TrialNature communications2025

A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.

Francesco Mazziotta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.